Immunosuppressive therapy of LGL leukemia: Prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998)

Leukemia

Volumn 29, Issue 4, 2015, Pages 886-894

  Loughran, T P ^a,i,j   Zickl, L ^b   Olson, T L ^a,j   Wang, V ^b   Zhang, D ^a   Rajala, H L M ^c   Hasanali, Z ^a   Bennett, J M ^d   Lazarus, H M ^e   Litzow, M R ^f   Evens, A M ^g,k   Mustjoki, S ^c   Tallman, M S ^h,l  

^a UNIVERSITY OF VIRGINIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e Division of Hematology/Oncology   (United States)

^f MAYO CLINIC   (United States)

^g Tufts Medical Centre   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^j PENN STATE CANCER INSTITUTE   (United States)

^k UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; FAS LIGAND; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; METHOTREXATE; MICRORNA 223; MYC PROTEIN; PREDNISONE; PURINE; STAT3 PROTEIN; TRANSCRIPTION FACTOR E2F1; VASCULAR CELL ADHESION MOLECULE 1; IMMUNOSUPPRESSIVE AGENT; STAT3 PROTEIN, HUMAN; TRANSCRIPTOME;

ADULT; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPENIA; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SCREENING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; HYPOXIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LOW DRUG DOSE; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MELENA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; OXIDATIVE PHOSPHORYLATION; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PURINE METABOLISM; RESPIRATORY CHAIN; RHEUMATOID ARTHRITIS; SURVIVAL TIME; UPREGULATION; AGED; CLINICAL TRIAL; COMPLICATION; DRUG MONITORING; FINLAND; GENE EXPRESSION REGULATION; GENETICS; INTERNATIONAL COOPERATION; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; SURVIVAL ANALYSIS; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA; CYCLOPHOSPHAMIDE; DRUG MONITORING; FEMALE; FINLAND; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNATIONAL COOPERATION; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; MALE; METHOTREXATE; MIDDLE AGED; MUTATION; NEUTROPENIA; STAT3 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; TRANSCRIPTOME; UNITED STATES;

EID: 84927692007     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.298     Document Type: Article

References (29)

1. Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood 1993; 82: 1-14.
2. Loughran Jr. TP, Kadin ME, Starkebaum G, Abkowitz JL, Clark EA, Disteche C et al. Leukemia of large granular lymphocytes: Association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med 1985; 102: 169-175.
3. Yang J, Epling-Burnette PK, Painter JS, Zou J, Bai F, Wei S et al. Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. Blood 2008; 111: 1610-1616.
4. Zhang R, Shah MV, Yang J, Nyland SB, Liu X, Yun JK et al. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci USA 2008; 105: 16308-16313.
5. Shah MV, Zhang R, Irby R, Kothapalli R, Liu X, Arrington T et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 2008; 112: 770-781.
6. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001; 107: 351-362.
7. Schade AE, Powers JJ, Wlodarski MW, Maciejewski JP. Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. Blood 2006; 107: 4834-4840.
8. Yang J, Liu X, Nyland SB, Zhang R, Ryland LK, Broeg K et al. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood 2010; 115: 51-60.
9. Pandolfi F, Loughran Jr. TP, Starkebaum G, Chisesi T, Barbui T, Chan WC et al. Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. Cancer 1990; 65: 341-348.
10. Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP Jr. The lymphoproliferative disease of granular lymphocytes: Updated criteria for diagnosis. Blood 1997; 89: 256-260.
11. Bareau B, Rey J, Hamidou M, Donadieu J, Morcet J, Reman O et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: A report on cases. Haematologica 2010; 95: 1534-1541.
12. Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: A T-cell clonopathy of undetermined significance? Blood 1994; 84: 1620-1627.
13. Neben MA, Morice WG, Tefferi A. Clinical features in T-cell vs natural killer-cell variants of large granular lymphocyte leukemia. Eur J Haematol 2003; 71: 263-265.
14. Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood 2011; 117: 2764-2774.
15. Koskela HL, Eldfors S, Ellonen P, Van Adrichem AJ, Kuusanmaki H, Andersson EI et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905-1913.
16. Kothapalli R, Nyland SB, Kusmartseva I, Bailey RD, McKeown TM, Loughran TP Jr. Constitutive production of proinflammatory cytokines RANTES, MIP-1beta and IL-18 characterizes LGL leukemia. Int J Oncol 2005; 26: 529-535.
17. Liu JH, Wei S, Lamy T, Epling-Burnette PK, Starkebaum G, Djeu JY et al. Chronic neutropenia mediated by fas ligand. Blood 2000; 95: 3219-3222.
18. Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 1999; 11: 709-719.
19. Gronowski AM, Zhong Z, Wen Z, Thomas MJ, Darnell Jr. JE, Rotwein P. In vivo growth hormone treatment rapidly stimulates the tyrosine phosphorylation and activation of Stat3. Mol Endocrinol 1995; 9: 171-177.
20. Smirnova E, Griparic L, Shurland DL, Van Der Bliek AM. Dynamin-related protein Drp1 is required for mitochondrial division in mammalian cells. Mol Biol Cell 2001; 12: 2245-2256.
21. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009; 324: 1713-6.
22. Phillips D, Reilley MJ, Aponte AM, Wang G, Boja E, Gucek M et al. Stoichiometry of STAT3 and mitochondrial proteins: Implications for the regulation of oxidative phosphorylation by protein-protein interactions. J Biol Chem 2010; 285: 23532-23536.
23. Hong YR, Chen CH, Cheng DS, Howng SL, Chow CC. Human dynamin-like protein interacts with the glycogen synthase kinase 3beta. Biochem Biophys Res Commun 1998; 249: 697-703.
24. Smolenska Z, Kaznowska Z, Zarowny D, Simmonds HA, Smolenski RT. Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 997-1002.
25. Pulikkan JA, Dengler V, Peramangalam PS, Peer Zada AA, Muller-Tidow C, Bohlander SK et al. Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood 2010; 115: 1768-1778.
26. Liu JH, Wei S, Lamy T, Li Y, Epling-Burnette PK, Djeu JY et al. Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood 2002; 100: 1449-1453.
27. Littler AJ, Buckley CD, Wordsworth P, Collins I, Martinson J, Simmons DL. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br J Rheumatol 1997; 36: 164-169.
28. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003; 9: 316-326.
29. Moignet A, Hasanali Z, Zambello R, Pavan L, Bareau B, Tournilhac O et al. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia 2014; 28: 1134-1136.